2026 Volume 20 Issue 4 Pages 361-372
Hepatocellular carcinoma (HCC) is governed by malignant progression and deterioration of the organ in which the cancer arises. Modern management has therefore outgrown static stage-to-treatment allocation. We define dynamic therapeutic opportunity as the time-varying set of clinically credible treatment options available to an individual patient, determined by hepatic reserve, oncological tractability, physiological reserve, prior therapeutic exposure, patient goals, and real-world deliverability. This framework does not replace validated staging systems or liver-function scores; it asks how each intervention changes the circumstances under which the next decision will be made. Evidence for curative-intent conversion remains dominated by selected cohorts, although the interim results of the randomized TALENTop trial provide the first prospective comparative signal supporting resection in a narrowly defined post-induction population. We review liver-sparing surgery, locoregional-systemic integration, conversion therapy, and modifiers such as frailty and metabolic dysfunction-associated steatotic liver disease. We then propose a trial architecture that complements tumor endpoints with hepatic decompensation, sustained ALBI deterioration, subsequent-treatment access, curative-intent transition, functional independence, and patient-reported outcomes. Modern HCC management should evaluate not only whether an intervention controls the present tumor but also whether it preserves, expands, or eliminates the patient's future set of clinically meaningful treatment options.
